

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <b>014835.77.02-034</b>		SERIAL NO. <b>10/527,904</b>	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b>				APPLICANT <b>Redfield, et al.</b>			
				FILING DATE <b>07-07-2005</b>		GROUP <b>1617</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINE R INITIAL		PATENT or APPLICATION NUMBER	ISSUE OR PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6096780	08-01-2000	Shiraishi et al.			
		6,013,644	1/11/2000	Mills, et al.			
		5,962,462	10/5/1999	Mills, et al.			
		6,150,530	11/21/2000	Kempf, et al.			
		5,994,136	11/30/1999	Naldini			
		20030099944	5/29/2003	Schaffer et al.			
		20030060457	3/27/2003	Schaffer et al.			
		DOCUMENT NUMBER	PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	CLASS	SUBCLASS	TRANSLATION YES      NO
		WO 99/48504	09-30-1999	Lisziwiewicz, et al.			
		WO 99/47146	09-23-1999	Lisziwiewicz, et al.			
		WO 02/053096	11 July 2002	Schaffer			
		WO 02/062123	15 August 2002	Anderson			
		WO98/25604	12/12/1997	Merck			
		WO00/51610	3/1/2000	Merck			
		WO02100401	6/5/2002	Schering			
		WO03/027671	9/25/2002	Eirx			
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
		ANDRIEU, et al. "Results of a 2-year exploratory study with cyclosporin a in human immunodeficiency virus infection." (1998) in <i>Autoimmune Aspects of HIV Infection</i> , eds. (R. Soc. Med. Services, London), pp. 191-194.					
		Paton, et al., "Hydroxychloroquine, hydroxycarbamide and didanosine as economic treatment for HIV-1" <i>The Lancet</i> , (2002) V.359, 1667					
		Spada, et al. "An Evaluation of Antiretroviral Therapy Associated with $\alpha$ -Tocopherol" <i>Clin. Chem.. Lab. Med</i> (2002) 40(5), 456-459.					
		Calabrese, L., Lederman, M., Spritzler, J., Coombs, R., Fox, L., Schock, B., Yen-Lieberman, B., Johnson, R., Mildvan, D. & Parekh, N. (2002) <i>J. Acquired Immune Defic. Syndr.</i> 29, 356-362.					
		Lori, et al. "Strucutured treatment interruptions as a potential alternative therapeutic regimen", <i>Journal of Antimicrobial Chaemotherapy</i> (2002) 50, 155-160.					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 <b>LIST OF DOCUMENTS CITED BY APPLICANT</b>		US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. <b>014835.77.02-034</b>	SERIAL NO. <b>10/527,904</b>
		APPLICANT <b>Redfield, et al.</b>		
		FILING DATE <b>07-07-2005</b>	GROUP 1617	
<p>Bjornal, A., Sonnerborg, A., Tscherning, C., Albert, J. &amp; Fenyo, E. (1999) <i>AIDS Res. Hum. Retroviruses</i> 15, 647-653.</p> <p>Loetscher, P., Seitz, M., Baggolini, M. &amp; Moser, B. (1996) <i>J. Exp. Med.</i> 184, 569-577.</p> <p>Morice, et al. (1993) <i>J. Biological Chemistry</i>, Vol 268 (5) pp. 3734-3738.</p> <p>Poon, M., Badimon, J. &amp; Fuster, V. (2002) <i>Lancet</i> 359, 619-622.</p> <p>Castedo, et al., (2002) <i>EMBO Journal</i>, 21 (15) pp. 4070-4080.</p> <p>Reeves J et al., (2002) <i>PNAS</i> 99: 16249-16254.</p> <p>Rizzardi, G., Harari, A., Capiluppi, B., Tambussi, G., Ellefsen, K., Ciuffreda, D., Champagne, P., Bart, P., Chave, J., Lazzarin, A. &amp; Pantaleo, G. (2002) <i>Clin. Invest.</i> 109, 681-688.</p> <p>Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) <i>Nat. Med.</i> 8, 128-135.</p> <p>Heredia, A; Amoroso, A; Davis, C.; Le, N.; Readon, E.; Klingebiel, E.; Gallo, R.C; and Redfield R.R. (2003) <i>Proc. Natl. Acad. Sci. USA</i>, 100 (18) 10411-10416.</p> <p>Heredia, A., Davis, C., Amoroso, A., Dominique, J., Le, N., Klingebiel, E., Reardon, E., Zella, D. &amp; Redfield, R. (2003) <i>Proc. Natl. Acad. Sci. USA</i> 100, 4179-4184.</p> <p>Heredia, A. et al, <i>Journal of Human Virology</i> 3(5): 248 (Sept-Oct 2000)</p> <p>Kahan, B. &amp; Camardo, J. (2001) <i>Transplantation</i> 72, 1181-1193.</p> <p>Kinter, A., Poli, G., Fox, L., Hardy, E. &amp; Fauci, A. (1995) <i>J. Immunol.</i> 154, 2448-2459.</p> <p>Lane, B., Markovitz, D., Woodford, N., Rochford, R., Strieter, R. &amp; Coffey, M. (1999) <i>J. Immunol.</i> 163, 3653-3661.</p> <p>Terada N, et al., (1993) <i>J of Cellular Phys.</i>, 154 pp 7-15.</p> <p>Ullman, K., Northrop, J., Verweij, C. &amp; Crabtree, G. (1990) <i>Annu. Rev. Immunol.</i> 8, 421-452.</p> <p>Ward, S., Bacon, K. &amp; Westick, J. (1998) <i>Immunity</i> 9, 1-11.</p> <p>Weissman, D., Dybul, M., Daucher, M., Davey, R., Walker, R. &amp; Kovacs, J. (2000) <i>J. Infect. Dis.</i> 181, 933-938.</p> <p>Willey, R., Smith, D., Lasky, L., Theodore, T., Earl, P., Moss, B., Capon, D. &amp; Martin, M. (1988) <i>J. Virol.</i> 62, 139-147.</p> <p>Zella, D., Riva, A., Weichold, F., Reitz, M. &amp; Gerna, G. (1998) <i>Immunol. Lett.</i> 62, 45-49.</p> <p>Roy, J., Sèbastien, J., Fortin, J. &amp; Tremblay, M. (2002) <i>Antimicrob. Agents Chemother.</i> 46, 3447-3455.</p> <p>Sehgal, S.-N. (1998) <i>Clin. Biochem.</i> 31, 335-340.</p> <p>Simmons, G., Clapham, P., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N. &amp; Proudfoot, A. E. (1997) <i>Science</i> 276, 276-279.</p> <p>Spina, C., Guatelli, J. &amp; Richman, D. (1995) <i>J. Virol.</i> 69, 2977-2988.</p>				
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				